Articles by Daniel Marsh
Nike Stock Retreats After Brief Recovery, Awaiting Q4 Earnings
Nike shares fell 2.41% on Friday, halting a brief rally. The stock remains near its 52-week low as the market looks ahead to a critical Q4 earnings report on June 30.
Boston Scientific Tumbles 16% on Watchman Slowdown; Focus Shifts to Monday's Reaction
Boston Scientific shares fell 16.4% last week after CEO Michael Mahoney warned of declining Watchman usage and flat growth through Q3. Wells Fargo downgraded the stock and slashed its price target.
Verizon Slips While S&P 500 and Nasdaq Notch Record Highs
Verizon closed at $47.81, down 0.42%, as major indexes hit record highs. The stock lags AI-driven rallies, trading on steady subscriber growth and a 2026 EPS outlook of $4.95–$4.99.
Verizon Dips as S&P 500 and Nasdaq Hit Record Highs
Verizon closed at $47.81, down 0.42%, while the S&P 500 and Nasdaq reached fresh highs. The stock underperforms amid AI-driven market euphoria.
Huntington Bancshares Surges on Heavy Volume, Regional Banking Outlook Brightens
Huntington Bancshares jumped 1.49% on double-average volume, outperforming regional peers. Q1 net income hit $523M, adjusted EPS 37¢, and Cadence Bank integration wraps in Q2. Management to present at Morgan Stanley June 9.
TechnipFMC Joins MSCI World Index, Shares End Week Down 3.6%
TechnipFMC shares ended Friday up 1.1% on heavy volume after joining the MSCI World Index, but the stock fell 3.6% for the holiday-shortened week. Q1 revenue rose 11.6% to $2.49 billion.
TechnipFMC Gains on MSCI Inclusion but Faces Volatility
TechnipFMC (FTI) closed at $68.42 on Friday, up 1.1% on heavy volume after MSCI World Index inclusion, but fell 3.62% for the week. Q1 revenue rose 11.6% to $2.49B, with subsea backlog at $16.47B.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Uber Under Pressure as Delivery Hero Bid Looms
Uber shares slipped nearly 2% last week to $70.40 as the market awaits a possible formal offer for Delivery Hero, with analysts flagging antitrust hurdles.
Healthpeak Retreats After Hitting 52-Week High: Key Factors Ahead
Healthpeak dropped 1.85% Friday, ending a 2.9% weekly decline after a 52-week high. The REIT raised its 2026 FFO outlook; analysts are split. Jobs data and rates are key.